Bionor Researchers to Present Data on Vacc-4x Phase IIB Trial at World Vaccine Congress, Washington, DC

[Washington, DC -- 12 April 2012] Researchers from Bionor Pharma have been invited to present data at the World Vaccine Congress, on 13 April 2012. Chief Scientific Officer Maja Sommerfelt will present quality controlled data with more details on the findings issued in 1Q 2012 indicating a statistically significant drop in viral load for patients who were given therapeutic HIV vaccine candidate Vacc-4x compared to those given a placebo.

About Bionor Pharma ASA

Bionor Pharma is a biopharmaceutical, listed company based in Oslo, Norway (OSE:BIONOR). The Company's investments in developing therapeutic vaccines are above US$60 million. Bionor's vaccines are based on the proprietary technology platform developed following more than two decades of research on peptides. The vaccines are designed to safely activate each person's immune system to combat viral disease.

The Company's lead investigational product, the HIV therapeutic vaccine Vacc-4x, has completed a phase IIb multinational (USA, Germany, UK, Spain and Italy), placebo controlled double-blind study, which found a statistically significant reduction in viral load in treated subjects. The second HIV therapeutic vaccine, Vacc-C5 is expected to be ready for first in man clinical trial 2Q 2012, and is developed to induce antibodies to HIV that can reduce immune hyper activation associated with HIV infection. Subsequent to the Vacc-C5 phase I/II trial, Bionor intends to combine Vacc-4x with Vacc-C5, a treatment that can potentially revolutionize the management of HIV infections and could form the basis for both a therapeutic and a preventative vaccine.

Bionor researchers will investigate three independent pathways to market for the HIV vaccine candidates Vacc-4x and Vacc-C5, through further clinical studies starting this year:

1. Vacc-4x revaccination in patients who participated in the phase IIb study, which aims to further reduce the viral load set point, during periods where patients are not on traditional medicine (antiretroviral therapy (ART)).

2. Vacc-4x combined with Revlimid® (lenalidomide), for patients with unmet medical needs, no longer responding well to ART.

3. Vacc-C5 clinical trial phase I/II, subsequent Vacc-C5 in combination with Vacc-4x.

The Company's innovative technology platform is also well suited to the development of vaccines for a wide range of other viral diseases, such as Influenza, HCV (Hepatitis C), HPV (Human Papilloma Virus) and CMV (Cytomegalovirus). All preclinical studies with Vacc-Flu (Universal Influenza vaccine) and Vacc-HCV (Hepatitis C vaccine), including toxicology are planned to be finalized in second half 2012.

More information about Bionor Pharma, its research and products, is available at www.bionorpharma.com.

# # #